☆ 4.7 Article

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes The SURPASS-5 Randomized Clinical Trial

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato et al.

Summary: In this study comparing Tirzepatide and glargine in patients with type 2 diabetes inadequately controlled on oral glucose-lowering medications, Tirzepatide demonstrated greater reduction in HbA(1c) and lower incidence of hypoglycemia at week 52, with no excess cardiovascular risk observed compared to glargine.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Julio Rosenstock et al.

Summary: Tirzepatide demonstrated significant improvements in glycemic control and body weight without increasing the risk of hypoglycemia. The safety profile was consistent with GLP-1 receptor agonists, suggesting a potential monotherapy use for the treatment of type 2 diabetes.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

Bernhard Ludvik et al.

Summary: The study aimed to compare the efficacy and safety of tirzepatide versus titrated insulin degludec in the treatment of type 2 diabetes. The results showed that tirzepatide had significant advantages in reducing HbA(1c) and bodyweight, and decreased the risk of hypoglycemia.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Juan P. Frias et al.

Summary: The study showed that Tirzepatide was both noninferior and superior to Semaglutide in terms of the mean change in glycated hemoglobin levels for patients with type 2 diabetes over 40 weeks. Additionally, reductions in body weight were greater with Tirzepatide compared to Semaglutide, with similar rates of gastrointestinal adverse events reported in both groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Endocrinology & Metabolism

Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis

Jessica A. Huthmacher et al.

DIABETES CARE (2020)

Add to Collection

Review Endocrinology & Metabolism

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

Laurie L. Baggio et al.

MOLECULAR METABOLISM (2020)

Add to Collection

Article Endocrinology & Metabolism

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial

Bernard Zinman et al.

DIABETES CARE (2019)

Add to Collection

Article Endocrinology & Metabolism

Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals

Laerke S. Gasbjerg et al.

DIABETES (2019)

Add to Collection

Article Endocrinology & Metabolism

Untitled

DIABETES OBESITY & METABOLISM (2018)

Add to Collection

Article Endocrinology & Metabolism

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

Helena W. Rodbard et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Juan Pablo Frias et al.

LANCET (2018)

Add to Collection

Article Pharmacology & Pharmacy

Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes

Maria Yu et al.

CLINICAL THERAPEUTICS (2017)

Add to Collection

Article Endocrinology & Metabolism

Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)

Paolo Pozzilli et al.

DIABETES OBESITY & METABOLISM (2017)

Add to Collection

Review Cell Biology

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action

Jonathan E. Campbell et al.

CELL METABOLISM (2013)

Add to Collection

Article Endocrinology & Metabolism

Insulin Therapy for Type 2 Diabetes

Sanne G. Swinnen et al.

DIABETES CARE (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.